|
KMID : 0371319760180120023
|
|
Journal of the Korean Surgical Society
1976 Volume.18 No. 12 p.23 ~ p.28
|
|
|
The Effects of Combination Chemotherapy with MFC for Adenocarcinoma in Man on the Levels of Rosette-forming T-lymphocytes
|
|
金鎭福/Kim, Jin-Pok
朴在甲/Park, Jae-Gahb
|
|
|
Abstract
|
|
|
Previous studies indicate that even short course of chemotherapy can suppress lost defence mechanisms, including antibody production and cellular immunity2,6,12,16,17) and immune supp-ression by chemical agents such as methotrexate, 5-fluorouracil, cyclophosphamide, prednisone, and 6mercaptopurine3,7~9,14,15) have been shown to facilitate tumor growth , in allogenic and syngenic animal systems.
We have been; generally -used the combination chemotherapy with mitomycin C, 5-fluorouracil-and cytosine arabinoside for adenocarcinoma of gastrointestinal tract after report of Ota et a1.13) but it was not known about the effects of MFC chemotherapy on the levels of rosette-forming T-lymphocytes.
Between October, 1975 and March, 1976, nonimmune rosette formation were used to evaluate the T-cell subpopulation of peripheral blood, lymphocytes in 26 post-operative adenocarcinoma patients including 9 patients 1 week -after cancer surgery and 17 patients under or after MFC chemotherapy schedule:
The mean percentages of rosette forming cells in the groups under or after MFC chemotherapy were not lower than the mean percentage of the patients before chemotherapy. The, percentage; was 62.7±l0. 1%(mean±S. D.) for the patients 1 week after cancer surgery, 63.2± 5.5% for, the 3 adenocarcinoma patients after 5 times of MFC chemotherapy, 61.5±8.39%, for the patients after 10 times administration and 63.1±7.0% for the patients 5-21 weeks after 10 times administration of MFC combination chemotherapy. Absolute T-lymphocyte counts in each group were 1, 246±650/mm3, 1,606±145/mms, 1, 237±536/mm3, and 1,077+302/mms but there was no statistically significant difference by F-test between, control group(1 week after cancer surgery) and other group under or after MFC chemotherapy. These new datas suggest that the schedule of MFC chemotherapy: may not produce significant suppression ´of circulating T-lymphocytes,
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|
|